R
heumatoid arthritis (RA) is an autoimmune inflammatory disease affecting 1% of the population and characterized by progressive joint destruction and debility. Early initiation of aggressive disease-modifying therapy is favored to optimize long-term outcome. However, diagnosis relies predominantly on clinical manifestations, many of which overlap with other inflammatory arthritides. A diagnostic test that is highly specific for RA and able to predict disease progression would be of great value to clinicians at the time of initial disease manifestations.
IgM rheumatoid factor (RF) is a serologic test widely considered a criterion for the diagnosis of RA, although it demonstrates low specificity as a result of its presence in other connective tissue diseases, some infectious diseases, and also in healthy individuals. Antikeratin antibodies and antiperinuclear factor, demonstrated by indirect immunofluorescence, are more specific for RA, although technical difficulties and problems with standardization have limited their use. These antibodies have been collectively renamed antifilaggrin antibodies because they react with (pro)filaggrin present in epidermis and human buccal mucosal cells. 1 It has recently been shown that the epitope for antifilaggrin antibodies contains citrulline, a neutral amino acid formed by deamination of arginine residues by the enzyme peptidylarginine deiminase. 1 A cyclic peptide variant containing citrulline, cyclic citrullinated peptide (CCP), was designed to enhance affinity for anticitrullinated peptide antibodies and used as the antigenic substrate in an enzymelinked immunosorbent assay (ELISA). 2 This test demonstrated a very high specificity for RA of 98% and a moderate sensitivity of 68%. 2 In this study, we aimed to evaluate an ELISA assay for anti-CCP by determining the prevalence of antibodies to CCP in outpatients with chronic arthritis attending a tertiary hospital clinic.
METHODS
The arthritis-monitoring clinic is an outpatient service at a tertiary teaching hospital in Sydney for patients with inflammatory arthropathies, predominantly RA, requiring regular monitoring while on disease-modifying therapy. Patients are diagnosed with RA by an experienced rheumatologist according to clinical features and with reference to 1987 American Rheumatism Association (ARA) criteria. 3 One hundred eighty-six patients are registered in the clinic database, most with longstanding disease. Patients selected for our study were those reviewed during March through June 2002 who underwent routine venipuncture for monitoring purposes. Blood samples were centrifuged and serum stored at Ϫ20°C until assayed.
Antibodies to CCP were measured using the QuantaLite CCP ELISA (INOVA, San Diego, CA) with supplied negative, low-positive, and high-positive controls. According to the manufacturer's instructions, 100 L of prediluted controls and patient samples at 1:101 dilutions were applied in duplicate to wells of a polystyrene microwell ELISA plate coated with purified CCP antigen. The plate was incubated for 30 minutes at room temperature and then washed 3 times. HRP IgG conjugate (100 L) was added to the wells for 30 minutes after which the wash procedure was repeated. TMB chromogen was added to each well and the plate incubated in the dark for 30 minutes. The color reaction was stopped using HRP stop solution and the absorbance (OD) of each well read immediately at 450 nm.
Results were calculated semiquantitatively according to the manufacturer's recommendations by first determining the average OD for each set of duplicates. This value was then divided by the average OD of the low-positive control, and then multiplied by the unit value assigned to the low-positive control to give a sample value in units. Manufacturer's cutoff values were used to generate semiquantitative results of negative, weak positive, moderate positive, and strong positive.
Each sample was also tested for the presence of (IgM) RF, performed by nephelometry (Beckman Coulter Immage) and considered positive if detected in serum at a level Ͼ20 international units (IU)/mL.
This study was performed before the enactment of legislation requiring patient consent for laboratory evaluation of an assay on deidentified serum samples.
RESULTS
Serum was collected from 12 male and 22 female patients. Twenty-six patients (76%) had detectable antibodies to CCP. Of these, 21 were high-positive, 2 moderate, and 3 low-positive. All positive results were grouped together to classify patients as either CCP-positive or -negative. RF was positive in 22 of 34 patients (65%); only 2 of these patients were negative for CCP antibodies.
RA was the clinical diagnosis in 29 patients. Diagnoses for the remaining 5 were juvenile rheumatoid arthritis, osteoarthritis, and psoriatic arthritis in 1 patient each, and nonspecific polyarthritis in 2 patients. Within the group of 29 patients with RA, 25 were positive for CCP antibodies and 21 patients positive for rheumatoid factor. Six patients with seronegative RA demonstrated the presence of CCP antibodies. One patient with a clinical diagnosis of psoriatic arthritis demonstrated positive results for both CCP antibodies (highpositive) and RF. This patient had a symmetric inflammatory arthropathy, psoriasis, and was negative for RF at initial presentation in 1984; current serologic findings suggest the clinical picture may indeed be the result of the coexistence of 2 common conditions: RA and psoriasis. All other patients with a diagnosis other than RA were negative for anti-CCP antibodies.
DISCUSSION
Antibodies to CCP have emerged as a serologic marker with high diagnostic specificity for RA.
Early testing with a CCP ELISA in patients with RA revealed a moderate sensitivity of 68% and an extremely high specificity of 98% for the disease.
2 CCP antibodies were detected in 35% of patients with RF-negative RA. Among patients with recent-onset arthritis, sensitivity was slightly lower (48%); however, specificity remained high (96%), suggesting the test would be particularly valuable for the early diagnosis of RA. 2 Another study evaluating an ELISA for CCP antibodies showed a diagnostic sensitivity of 41% and a specificity of 98% for RA. RF had a higher sensitivity (62%) and a lower specificity (84%) compared with anti-CCP. Specificity was increased to 99.6% when both antibody assays were used. This study demonstrated that high quantitative levels of CCP antibodies occurred almost exclusively in RA. 4 In addition to their role in early diagnosis, CCP antibodies are increasingly recognized as prognostic markers for disease severity and radiologic progression. Their presence in RA is associated with indicators of disease severity such as erosions, functional disability, and absence of remission. 5 The sensitivity and positive predictive value for erosive disease at 2 years in CCP-positive patients was shown to be 63% and 91%, respectively, comparable to the predictive value of RF status. 2 Kroot et al followed a group of 273 patients with recently diagnosed RA, 66% of whom were positive for CCP antibodies at study entry. Six years later, those patients with anti-CCP antibodies had developed significantly more severe radiologic damage when compared with CCP-negative patients. IgM RF was the strongest predictor of progression, and the additional predictive value of anti-CCP positivity was only moderate. The presence of CCP antibodies did not predict functional disability during the follow-up period. 6 A more recent study evaluating CCP antibodies and prediction of radiologic damage found that radiologic damage, erosion, and joint narrowing were more severe in patients with RA with anti-CCP antibodies after 3 years follow up. Anti-CCP antibody was superior to RF in predicting total joint damage and radiologic progression at 5 years. 7 The combined analysis of anti-CCP and IgM RF results increases the ability to predict erosions and disease progression in RA. 8 The role of citrullinated peptides in the pathogenesis of RA remains controversial. Although antifilaggrin antibodies are specific for RA, the disease does not affect tissues containing citrullinated (pro) filaggrin such as skin and buccal mucosa, and filaggrin is not present in joints. The presence of intracellular citrullinated proteins has been demonstrated in synovial biopsies of patients with RA but not in disease controls. Citrulline immunoreactivity colocalized with antifilaggrin antibody reactivity, despite the absence of filaggrin. The authors propose that citrullinated proteins in synovial tissue associated with nonfilaggrin proteins may be the trigger of the autoimmune response. 9 Reparon-Schuijt confirmed that anti-CCP precursor B cells are a normal component of the B cell repertoire by demonstrating their presence in peripheral blood of both patients with RA and healthy controls. These B cells only produce anti-CCP antibodies on activation. In contrast, the synovial fluid and bone marrow compartments of patients with CCP-seropositive RA contain a population of B cells that spontaneously secrete anti-CCP antibodies. The presence of anti-CCP-secreting cells in inflamed joints further suggests local antigen-driven B cell maturation at the site of inflammation in RA. 10 Consistent with another study that has detected anti-CCP antibodies in up to 80% of patients with longstanding disease, 11 we have demonstrated a very high prevalence (86%) of antibodies to CCP in our group of patients with longstanding RA. This is at variance with studies evaluating the sensitivity of the test in early disease that have shown much lower detection rates of 48% to 66%. 2, 6 The discrepancy between these results may be explained by seroconversion of patients with increasing disease duration. Consistent with this hypothesis, Schellekens found that after 1-year follow up of early arthritis clinic patients, 8% had converted from anti-CCP-negative to -positive. 2 The precise clinical role of testing for antibodies to CCP remains to be determined. IgM RF remains a useful test with good sensitivity and an association with disease severity, but the advantages of anti-CCP antibodies are high disease specificity, presence in some RF-seronegative patients, ability to diagnose early RA as well as offering additional prognostic information. Our cross-sectional study has demonstrated a high prevalence of high-titer antibodies to CCP in patients with chronic RA requiring disease-modifying drug therapy, including the identification of a group of RF-negative, anti-CCP-positive patients. To our knowledge, this is the first report of the prevalence of anti-CCP antibodies in an Australian population.
